Abstract
Evasion of the immune-mediated cytotoxicity is an all too common hallmark of cancer. A recent study revealed that cancer vaccination - through the establishment of tumor reactive CD8+ CTLs- drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype and they identified the transcription factor Nanog as a pivotal player in this process. Tellingly, the suppression of Nanog expression via using Nanog siRNA renders tumour cells more sensitive to immune response and leads to reduction of tumour growth. Taken together, the results of these studies support the notion that inhibiting Nanog may have therapeutic implications with respect to immune-based cancer therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Cancer Prevention & Current Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
